|
業務類別
|
Biotechnology |
|
業務概覽
|
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis. |
| 公司地址
| 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305 |
| 電話號碼
| +1 763 496-5454 |
| 傳真號碼
| +1 763 710-4456 |
| 公司網頁
| https://www.diamedica.com |
| 員工數量
| 28 |
| Mr. David J. Wambeke |
Chief Business Officer |
-- |
17/03/2025 |
| Mr. Scott Kellen |
Chief Financial Officer, Principal Accounting Officer and Secretary |
美元 374.25K |
17/03/2025 |
| Mr. Rick Pauls |
Director, President and Chief Executive Officer |
美元 593.25K |
28/03/2025 |
| Dr. Julie Krop, M.D. |
Chief Medical Officer |
-- |
06/08/2025 |
|
|
| Ms. Tanya N. Lewis, M.S. |
Independent Director |
28/03/2025 |
| Mr. Charles P. Semba, M.D. |
Independent Director |
28/03/2025 |
| Dr. Richard E. Kuntz, M.D.,M.Sc. |
Independent Director |
28/03/2025 |
| Mr. Rick Pauls |
Director, President and Chief Executive Officer |
28/03/2025 |
| Mr. James T. Parsons |
Chairman of the Board |
06/03/2025 |
| Dr. Michael Giuffre, M.D. |
Independent Director |
28/03/2025 |
| Mr. Daniel J. O’Connor, J.D. |
Director |
24/02/2025 |
|
|
|
|
